LIUHUIHUI
Lv1
20 积分
2022-09-16 加入
-
Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy
7天前
已完结
-
Evaluation of Treatment Efficacy of Tyrosine Kinase Inhibitors in Rare Single EGFR Exon 21 L861Q Mutation: Single Center Experience
8天前
已完结
-
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations
8天前
已完结
-
FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations
8天前
已关闭
-
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
1个月前
已完结
-
ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK ) non-small cell lung cancer (NSCLC)
1个月前
已关闭
-
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
-
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma
2个月前
已完结
-
Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers
2个月前
已完结
-
Effects of voriconazole and fluconazole on the pharmacokinetics of almonertinib in rats by UPLC-MS/MS
2个月前
已完结